Generian is developing therapies that restore cellular function, amplifying natural signaling networks to reverse the course of disease. Generian's small molecules are designed to inhibit specific E3 ligase substrate-binding complexes, thereby preventing the degradation of beneficial target proteins and enhancing downstream cellular responses.
Generian is using its proprietary platform to advance its first-in-class programs for diseases with unmet need. Generian is exploring partnership opportunities for new target discovery to further develop this powerful platform.
